Background: Advanced Hybrid Closed Loop (AHCL) systems, MiniMed 780G (M) and Tandem Control-IQ (T), represent the most advanced technologies for glycemic control in patients with Type 1 Diabetes. Very limited comparison data are available in the literature yet. Aim: To identify differences in performance between M and T in adult and pediatric patients using AHCL for at least 1 year. Method: We retrospectively collected clinical and ambulatory glucose profile data of AHCL users right before M or T initiation and 6 and 12 months later. We enrolled 187 patients with Type 1 Diabetes, 93 adults (>18 yo; 57M, 36T), 49 adolescents (age 13-18 yo; 6M, 43T) and 45 children (<13 yo; 4M, 41T). Target-TIR was set at >70%. Results: No differences in doses of insulin/kg between the two AHCL were detected at 6 and 12 months in the 3 groups. Adults: Patients with M vs T had higher TIR at 6 months (median[IQR] 74%[65-80] vs 66% [60-74]; p=.036) and 12 months (75% [69-84] vs 67% [58-74]; p=.002). Significant improvement in patients using M vs T was also seen in TAR>250mg/dl and GMI at 6 (p=.013, .006) and at 12 months (p=.001, .007). At 12 months, 68% of M users had a target-TIR vs 42% T (p=.044). Adolescents: Patients with M vs T had lower TAR>250mg/dl and CV at 6 months (p<.001,=.006) and at 12 months (p=.003, .023) and higher TIR (6 mo: 80%[71-90] vs 60%[50-71], p=.001; 12 mo: 68% [65-85] vs 58%[46-69], p=.013). TBR at 12 months was higher in M vs T users (3% [2-4] vs 1% [0-2], p=.009). At 6 months, 83% of M users had a target-TIR vs 24% T (p=.011); at 12 months 96% of T users had a target-TBR vs 50% M (p=.016). Children: no significant differences were seen between M/T users, but with a small cohort of M users. Conclusion: With similar insulin/kg, M seems to be more effective in improving TIR, TAR and CV in adults and adolescents but T appears to be better in reducing TBR in adolescents at 12 mo.